A study by LiveWell Initiative’s Global Public Health University (GPHU) in collaboration with frontline healthcare workers in Nigeria tested 4-Aminoquinolines as prophylaxis for COVID-19 in Nigeria, recorded some significant level of success. Quinine crosses the blood-brain barrier into the alveoli which gives it an added advantage over chloroquine and hydroxychloroquine in COVID-19 and picks up where CQ/ HCQ stop. The study was a random Physician – Patient Trials at the discretion of Prescribing Clinicians and Clinical Researchers, they are as recommended. The preliminary data analyzed using Microsoft excel, were from 123 study participants (110 used as prophylaxis and 23 as treatment). CQ/HCQ is also relevant for Inpatient care as the 11 Laboratory Tested Positive Patients placed on admission at the COVID-19 Isolation Center who were treated with CQ are all fully recovered, up to 6 weeks post-lockdown with no relapse, and having tested negative twice post treatment. Quinine works in advanced COVID-19 as the Single Laboratory Tested Positive client on the ventilator, were fully recovered after Treatment with I.V. Quinine and is still symptom free 6 weeks post-lockdown. The tests were re-run through the second, third wave, Delta and Omicron stages. The further results will be discussed in subsequent papers scheduled for publication.
| Published in | European Journal of Clinical and Biomedical Sciences (Volume 8, Issue 4) |
| DOI | 10.11648/j.ejcbs.20220804.12 |
| Page(s) | 62-70 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
GPHU (Global Public Health University), LWIA (LiveWell Initiative Academy), CQ (Chloroquine), HCQ (Hydroxychloroquine), rRT-PCR (Rapid Test – Polymerase Chain Reaction), HCWs (Healthcare Workers), COVID-19 (Coronavirus Disease), MPH (Masters in Public Health)
| [1] | Huang C, Wang Y, Ren L, Zao J, Hu. Y et al. Clinical features of patients infected with 2019 novel. Coronavirus in Wuhan China. Lancet 2020 DOI: 10.1016/SO140-6736(20)30183-5. |
| [2] | World Health OrganizationNovel Coronavirus (2019-nCoV) Available at https://www.who.int/emergencies/novelcoronavirus-2019. Accessed February 7, 2020. |
| [3] | World Health Organization 2019-nCoV Situation Report. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/. Accessed February 7, 2020. |
| [4] | World Health Organization 2019-nCoV Situation Report. https://apps.who.int/iris/bitstream/handle/10665/331935/SITREP_COVID-19_WHOAFRO_20200429-eng.pdf |
| [5] | Kakodkar P, Kaka N, Baig MN, A Comprehensive Literature Review on Clinical Presentation, and Management of the Pandemic Coronavirus Disease. [A Review] Cureus. 2020 Apr 06; 12 (4): e7560. |
| [6] | Centor RM, Kim AH, Sparks JA. Annals On Call - COVID-19: Is Chloroquine the Answer?Ann Intern Med. 2020 Apr 09 [Online ahead of print]. |
| [7] | Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. [Journal Article] CMAJ. 2020 Apr 08 [Online ahead of print]. |
| [8] | Study Protocols for COVID-19 RESPONSE IN AFRICA – An African Solution to the Pandemic. Bright B, Ali W, Adesope T https://www.slideshare.net/BisiBright/study-protocols-for-covid-19-response-in-africa-an-african-solution-to-the-pandemic |
| [9] | Revised advisory on the use of Hydroxychloroquine (HCQ) as prophylaxis for SARS-CoV-2 infection (in supersession of previous advisory dated 23rd March, 2020) - Indian Council of Medical Research https://www.icmr.gov.in/pdf/covid/techdoc/V5_Revised_advisory_on_the_use_of_HCQ_SARS_CoV2_infection.pdf |
| [10] | Abdel Ghaffar MM, Omran D, Elgebaly A, Bahbah EI, Afify S, AlSoda M, et al. (2022) Prediction of mortality in hospitalized Egyptian patients with Coronavirus disease-2019: A multicenter retrospective study. PLoS ONE 17 (1): e0262348. https://doi.org/10.1371/journal. pone.0262348 |
| [11] | Otto MA. Wuhan virus: What clinicians need to know. Medscape Medical News. 2020, [cited 2020 Jan 27]. Available from: https://www.medscape.com/viewarticle/924268. |
| [12] | Chan Jasper FW, Yuan S, Kok KH, To Kelvin KW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020DOI: https://doi.org/10.1016/S0140-6736(20)30154-9 |
| [13] | Perlman S. Another decade, another coronavirus. N Engl J Med 2020 DOI: 10.1056/NEJMe2001126. |
| [14] | World Health Organization. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected-Interim Guidance. 2020, [cited 2020 Feb 18]. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected |
APA Style
Bisi Bright, Patrick Sobande, Temitope Alonge, Chinedum Peace Babalola, Adewale Abdul-Semiu Musa-Olomu, et al. (2022). Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU. European Journal of Clinical and Biomedical Sciences, 8(4), 62-70. https://doi.org/10.11648/j.ejcbs.20220804.12
ACS Style
Bisi Bright; Patrick Sobande; Temitope Alonge; Chinedum Peace Babalola; Adewale Abdul-Semiu Musa-Olomu, et al. Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU. Eur. J. Clin. Biomed. Sci. 2022, 8(4), 62-70. doi: 10.11648/j.ejcbs.20220804.12
AMA Style
Bisi Bright, Patrick Sobande, Temitope Alonge, Chinedum Peace Babalola, Adewale Abdul-Semiu Musa-Olomu, et al. Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU. Eur J Clin Biomed Sci. 2022;8(4):62-70. doi: 10.11648/j.ejcbs.20220804.12
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ejcbs.20220804.12,
author = {Bisi Bright and Patrick Sobande and Temitope Alonge and Chinedum Peace Babalola and Adewale Abdul-Semiu Musa-Olomu and Wael Ali and Olayinka Kotila and Niyi Fajimi and Ewaoche Sunday Itodo and Seun Falayi and David Ajayi and Adebola Olatunji and Toyin Adesope and Fidelis Ojeblenu and Modupe Ologunagba and Aduh and Rilwan Rotinwa and Gbenga Odunfa and Arinzechchukwu Chukwurah and Sylvester Adeyemi},
title = {Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU},
journal = {European Journal of Clinical and Biomedical Sciences},
volume = {8},
number = {4},
pages = {62-70},
doi = {10.11648/j.ejcbs.20220804.12},
url = {https://doi.org/10.11648/j.ejcbs.20220804.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ejcbs.20220804.12},
abstract = {A study by LiveWell Initiative’s Global Public Health University (GPHU) in collaboration with frontline healthcare workers in Nigeria tested 4-Aminoquinolines as prophylaxis for COVID-19 in Nigeria, recorded some significant level of success. Quinine crosses the blood-brain barrier into the alveoli which gives it an added advantage over chloroquine and hydroxychloroquine in COVID-19 and picks up where CQ/ HCQ stop. The study was a random Physician – Patient Trials at the discretion of Prescribing Clinicians and Clinical Researchers, they are as recommended. The preliminary data analyzed using Microsoft excel, were from 123 study participants (110 used as prophylaxis and 23 as treatment). CQ/HCQ is also relevant for Inpatient care as the 11 Laboratory Tested Positive Patients placed on admission at the COVID-19 Isolation Center who were treated with CQ are all fully recovered, up to 6 weeks post-lockdown with no relapse, and having tested negative twice post treatment. Quinine works in advanced COVID-19 as the Single Laboratory Tested Positive client on the ventilator, were fully recovered after Treatment with I.V. Quinine and is still symptom free 6 weeks post-lockdown. The tests were re-run through the second, third wave, Delta and Omicron stages. The further results will be discussed in subsequent papers scheduled for publication.},
year = {2022}
}
TY - JOUR T1 - Telling the COVID-19 Story – An Overview of Our COVID-19 Study Protocols and Research at Livewell Initiative LWI and Global Public Health University GPHU AU - Bisi Bright AU - Patrick Sobande AU - Temitope Alonge AU - Chinedum Peace Babalola AU - Adewale Abdul-Semiu Musa-Olomu AU - Wael Ali AU - Olayinka Kotila AU - Niyi Fajimi AU - Ewaoche Sunday Itodo AU - Seun Falayi AU - David Ajayi AU - Adebola Olatunji AU - Toyin Adesope AU - Fidelis Ojeblenu AU - Modupe Ologunagba AU - Aduh AU - Rilwan Rotinwa AU - Gbenga Odunfa AU - Arinzechchukwu Chukwurah AU - Sylvester Adeyemi Y1 - 2022/07/28 PY - 2022 N1 - https://doi.org/10.11648/j.ejcbs.20220804.12 DO - 10.11648/j.ejcbs.20220804.12 T2 - European Journal of Clinical and Biomedical Sciences JF - European Journal of Clinical and Biomedical Sciences JO - European Journal of Clinical and Biomedical Sciences SP - 62 EP - 70 PB - Science Publishing Group SN - 2575-5005 UR - https://doi.org/10.11648/j.ejcbs.20220804.12 AB - A study by LiveWell Initiative’s Global Public Health University (GPHU) in collaboration with frontline healthcare workers in Nigeria tested 4-Aminoquinolines as prophylaxis for COVID-19 in Nigeria, recorded some significant level of success. Quinine crosses the blood-brain barrier into the alveoli which gives it an added advantage over chloroquine and hydroxychloroquine in COVID-19 and picks up where CQ/ HCQ stop. The study was a random Physician – Patient Trials at the discretion of Prescribing Clinicians and Clinical Researchers, they are as recommended. The preliminary data analyzed using Microsoft excel, were from 123 study participants (110 used as prophylaxis and 23 as treatment). CQ/HCQ is also relevant for Inpatient care as the 11 Laboratory Tested Positive Patients placed on admission at the COVID-19 Isolation Center who were treated with CQ are all fully recovered, up to 6 weeks post-lockdown with no relapse, and having tested negative twice post treatment. Quinine works in advanced COVID-19 as the Single Laboratory Tested Positive client on the ventilator, were fully recovered after Treatment with I.V. Quinine and is still symptom free 6 weeks post-lockdown. The tests were re-run through the second, third wave, Delta and Omicron stages. The further results will be discussed in subsequent papers scheduled for publication. VL - 8 IS - 4 ER -
Information
Email: